Wang et al. developed albumin and lactoferrin-based nanoparticles that effectively crossed the BBB by targeting low-density lipoprotein receptor-related protein-1 (LRP-1), which is overexpressed in both BBB endothelial cells and glioma cells. This evidence concerns the gene LTF and central nervous system cancer.